Zika Virus Is a Clinical Outlier Flavivirus {#sec0005}
===========================================

Rising from obscurity 60 years after its discovery, ZIKV caused the first major human epidemic in the Federated States of Micronesia, followed by a major pandemic with its introduction in Brazil sometime in 2013 [@bib0005]. Currently, indigenous mosquito-borne ZIKV transmission has been confirmed in 49 countries or territories of the AmericasAppendix A. The introduction and spread of ZIKV in the Americas was marked by the appearance of severe adverse outcomes such as fetal loss [@bib0010], **congenital Zika syndrome (CZS)** (see [Glossary](#glo0005){ref-type="glossary"}) [@bib0015], **Guillain--Barré syndrome (GBS)** [@bib0020], and rare cases of encephalopathy [@bib0025], meningoencephalitis [@bib0030], myelitis [@bib0035], uveitis [@bib0040], and severe thrombocytopenia [@bib0045]. Several hypotheses have been put forward to explain the unprecedented observed pathogenicity of ZIKV infection in the Americas, including prior heterologous flavivirus infection, virulence of the virus, host genetics and environmental factors among others.

ADE: From *In Vitro***Evidence to Clinical Relevance** {#sec0010}
======================================================

Analogous to **antibody-dependent enhancement (ADE)**, during secondary DENV exposure, the scientific community hypothesized that a ZIKV infection following a previous DENV infection may result in increased ZIKV pathogenesis (for example CZS and GBS) in the Americas. ADE *in vitro* can be considered as a common experimental phenomenon with uncertain clinical relevance, as it has been demonstrated for many viruses (alphaviruses [@bib0050], rabies [@bib0055], coxsackievirus B3 [@bib0060], coronavirus [@bib0065], human immunodeficiency virus [@bib0070], [@bib0075], and others) without evidence of worsened disease during secondary infection in mice or in human populations [@bib0080]. Such a precise ADE definition is very specific in describing an experimental finding as a fact. In *in vitro* assays, immune sera from patients exposed to a variety of different flaviviruses, including yellow fever and Japanese encephalitis viruses, will also enhance DENV infection [@bib0085]. Even the homotypic serotype responsible for a past DENV infection can induce ADE of DENV, if the serum is diluted to subneutralizing concentrations [@bib0090]. However, in contrast to ADE described for other viruses, ADE of DENV *in vivo* is commonly associated with a worse clinical outcome [@bib0095]. Secondary DENV infections result in dramatic clinical impairment along with a cytokine storm characterized by the increase in interleukin-6 (IL-6), IL-8, IL-10, interferon-γ (IFN-γ), IFN-α, and vascular endothelial growth factor (VEGF), combined with tumor necrosis factor-α (TNF-α), indicating a poor prognostic outcome [@bib0100] ([Figure 1](#fig0005){ref-type="fig"} ). Because of this, ADE related to flaviviruses should not be seen only as a single biological process of virus--antibody interaction. Defining ADE in the context of pathogenesis, as we usually read the outcome of the biological process, should imply a clinical consequence, including clinical and laboratory evidence of impairment. In this way, ADE would be defined as a common experimental *in vitro* phenomenon but a rare *in vivo* occurrence leading to worsening of the clinical presentation usually associated with hemodynamic changes, increased viremia, proinflamatory cytokine profile, and other detectable laboratory alterations.Figure 1Antibody-Dependent Enhancement (ADE) of Dengue and Zika Virus. ADE during a secondary heterologous Dengue virus infection has been documented *in vitro*, in mice, in non-human primates, and in humans playing a key role in the worsening of the clinical presentations. In contrast, ADE of Zika virus by pre-existing immunity to Dengue virus can be induced *in vitro*, and in immunodeficient mice. However, there is no evidence to support ADE occurring in non-human primates or in humans.Figure 1

Dengue Induced ZIKV ADE? {#sec0015}
========================

The debate of whether ZIKV ADE by flavivirus immune serum has recently increased because of results showing an increase in ZIKV pathogenesis in a mouse model (Stat2−/−) [@bib0105]. Using this model, Bardina *et al.* showed that, by administering DENV and West Nile virus (WNV) immune serum intraperitoneally, in an appropriate concentration before ZIKV infection, this resulted in fever and weight loss with an increased mortality as compared to some of the animals administered serum from flavivirus-naïve individuals [@bib0105]. However, results from the same work, in a dose-dependent evaluation of mouse survival and the clinical presentation experiment, revealed that control plasma at the highest concentration could also decrease mice survival by about 40%, similar to the effect of DENV immune plasma at the lowest dilutions. In addition to proving that antibodies induced by prior DENV infection, administered under different concentrations, can amplify or neutralize ZIKV disease manifestations *in vivo*, Bardina *et al.* also showed the limited value of ADE *in vivo* in immunosuppressed mice.

Indeed, ADE of ZIKV by previous flavivirus infection is not a novel concept. Back in 1987 Fabgami *et al.* demonstrated that ZIKV replication can be enhanced in P388D1 macrophage cell line by subneutralizing concentrations of antibodies in immune ascitic fluids from six other different flaviviruses, including Wesselsbron, Uganda S, WNV, Dakar bat, yellow fever and Potiskum virus [@bib0110]. However, the following facts might anticipate the unlikelihood of DENV-induced ZIKV ADE (as defined above) in humans: (i) there is no epidemiological or clinical evidence of DENV ADE with any other closely related flavivirus or any other viruses; (ii) before its introduction into the Western hemisphere, ZIKV continuously circulated in flavivirus-endemic areas (such as Africa and Southeast Asia), and an increase in ZIKV pathogenesis has not been reported in these locations; (iii) not all heterologous flavivirus immunity is the same, including the sequence in which infection occurs with different DENV serotypes [@bib0090], [@bib0095].

What Non-human Primates (NHPs) Can Tell Us {#sec0020}
==========================================

NHPs are natural hosts (in the sylvatic transmission cycle) supporting the replication of both DENV and ZIKV. For many years NHPs have been used as a surrogate for human infection in order to understand DENV pathogenesis and to test for vaccine immunogenicity and efficacy [@bib0115] -- and, more recently, for ZIKV replication and pathogenesis [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140]. In the past, DENV ADE, in terms of viral replication enhancement, has also been proven in NHPs after secondary DENV infection with DENV 2 [@bib0145] or by passive administration of optimal dilutions of human DENV-immune serum to the animals [@bib0150], or by using specific concentrations of a monoclonal antibody [@bib0155]. In addition to being useful for studying DENV pathogenesis, NHPs are a good model for predicting the behavior of different DENV vaccines in humans and for characterizing specific DENV neutralizing antibodies also occurring naturally in human populations [@bib0115]. Because of this, it is plausible to anticipate that data on ZIKV pathogenesis in NHPs can also reproduce or predict what will happen in humans. In a recent study, using a limited number of animals, Pantoja *et al.* were unable to show ADE of ZIKV in DENV immune macaques [@bib0160]. However, results showed that previous immunity to DENV was able to modulate the innate and cellular immune response to ZIKV with a tendency to lower the average ZIKV viremia days, to limit the increase in liver enzymes, and to induce a significant increase in the plasma perforin as evidence of an increased cytotoxic T cell activity [@bib0165]. This cellular immune response in NHPs is supported by recent results from human samples showing that prior DENV infection leads to stronger and faster responses to ZIKV in terms of both CD4 and CD8T cell responses, thus providing evidence of a biological outcome [@bib0170].

Human Evidence of ZIKV ADE? {#sec0025}
===========================

Coincident with the report by Pantoja *et al.*, a study on ADE of a human cohort was published [@bib0175]. Terzian *et al.* evaluated a cohort of ZIKV-infected patients and looked for previous DENV exposure and its relationship to viral load, cytokine profile, and clinical symptoms. Despite the suggestions from *in vitro* studies that ADE could occur in DENV-primed ZIKV-infected patients, the authors found no evidence that the presence of DENV antibodies changes the outcome of ZIKV infection in all tested parameters [@bib0175]. Collectively, these observations from NHPs and human cohorts strongly suggest that previous exposure to DENV does not have a deleterious effect in the clinical outcome of ZIKV infection. Supported by these observations, we can propose that the DENV-induced ZIKV ADE *in vitro* does not exist *in vivo* or that it is so uncommon that it might be not relevant as an epidemiological phenomenon.

Concluding Remarks {#sec0030}
==================

In summary, data from NHPs and humans, and from several serological studies [@bib0180], [@bib0185], do not support the suggestion that ZIKV may be enhanced *in vivo* by previous exposure to DENV. On the other hand, the few experimental lines of evidence that have addressed ADE of DENV induced by ZIKV-immune serum, as expected, have shown different degrees of *in vitro* and *in* vivo increase in DENV replication and pathogenesis respectively [@bib0190], [@bib0195].

Recently George *et al.* reported that an infection with DENV, after a short period of exposure to ZIKV, can enhance DENV infection in NHPs [@bib0200]. This is a very interesting report as it is expected that ZIKV-induced DENV cross-reacting antibodies, induced early after infection, may either neutralize or have no effect in DENV infection outcome. In any case, this report confirms the need for large studies in NHPs and for epidemiological data from the dengue-naïve human population that has been exposed to ZIKV during the recent epidemic.

Lastly, inferences derived from *in vitro* experiments and from immunologically modified animals will need to be carefully assessed due to the impact they can have on the approaches for ZIKV and DENV vaccines and therapeutics currently under development.Outstanding QuestionsWhat is the role of the time interval between a primary DENV and a subsequent ZIKV infection in the antibody and T cell immune response?How will this scenario compare to having ZIKV infection following two or more DENV or other flavivirus infections?How will this timing between infections impact the clinical outcome, if at all?With the recent ZIKV epidemic there is a substantial population that is ZIKV-positive/DENV-negative. Are these people at risk of having worse clinical presentations or are they partially protected against DENV?What will be the effect of a ZIKV component in the effectiveness of DENV vaccines currently in clinical trials or the one that has been licensed in some countries?What is the susceptibility conferred on the population by the DENV and ZIKV vaccines to subsequent heterogonous natural infections with those viruses?

**Antibody-dependent enhancement (ADE)**

:   a mechanism when non-neutralizing antibodies facilitate virus entry into host cells, leading to increased infectivity in the cells and exacerbation of the clinical disease.

**Congenital Zika syndrome (CZS)**

:   a pattern of birth defects found among fetuses and babies infected with ZIKV during pregnancy.

**Guillain--Barré syndrome (GBS)**

:   an autoimmune disorder affecting the peripheral nervous system. Initial symptoms are weakness and numbness in the extremities, which eventually develop into paralysis and, if untreated, death.

Resources {#sec0035}
=========

^i^ [www.who.int/entity/csr/resources/publications/zika/classification/en/](http://www.who.int/entity/csr/resources/publications/zika/classification/en/){#intr0005}
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